UroGen Pharma Ltd.: financial analysis
Ratios worked out from 10 fiscal years of UroGen Pharma Ltd.'s statements, compared with 671 companies in Biotechnology.
UroGen Pharma Ltd. scorecard#
Passes 6 of the 17 checks that could be worked out: strongest in growth (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 15, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median16.3×Price to sales 16.3× against Biotechnology's median of 8.2×.
- ✗Free cash flow yield above 5%-9.1%Free cash flow is -9.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year21.4%Revenue up 21.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years19.5%19.5% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median19.5%19.5% a year against Biotechnology's median of 12.8% (182 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$153 M-$153 M in fiscal 2025 against -$128 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$153 MNet income -$153 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-113.7%-113.7% against Biotechnology's median of -60.5% (244 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-113.7%-113.7% in fiscal 2025 against -122.8% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.0×Current ratio 4.01 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.86Z-score -3.86 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 6 years in a row.
Worth a look
- Net loss of $153 million, the 11th loss-making year in a row.
- Free cash flow was negative: -$163 million.
- Shareholders' equity is negative: -$105 million.
- Receivables grew 63% while revenue grew 21%: customers are paying later, or sales were booked ahead of cash.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profitno
- Long-term debt fell against assetsno
- Current ratio roseno
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.70 | × 1.2 | 0.84 |
| Retained earnings to assets | -4.79 | × 1.4 | -6.70 |
| Operating income to assets | -0.62 | × 3.3 | -2.06 |
| Market value to liabilities | 5.87 | × 0.6 | 3.52 |
| Revenue to assets | 0.55 | × 1 | 0.55 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 88.7% | 90.2% | 88.7% | 88.1% | 89.3% | 75.5% | 74% | |
| Operating margin | -113.7% | -107.1% | -79.2% | -122.8% | -192.1% | -60.5% | 40% | |
| Net margin | -139.8% | -140.3% | -123.6% | -170.6% | -230.7% | -70.4% | 38% | |
| Return on equity | — | — | — | — | -211.6% | -60.4% | — | |
| Return on assets | -63.1% | -54.7% | -65.1% | -86.0% | -91.7% | -44.3% | 34% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 21.5% | 9.3% | 28.5% | 34.0% | 307.1% | 15.6% | 58% | |
| Revenue growth, 3 years a year | 19.5% | 23.5% | 91.4% | — | — | 12.8% | 59% | |
| Revenue growth, 5 years a year | 56.2% | — | — | — | — | 15.3% | 86% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | — | — | — | — | 0.00× | 0.26× | — | |
| Net debt | $14 M | $-50 M | $4 M | $42 M | $-44 M | $-16 M | 27% | |
| Current ratio | 4.01× | 6.01× | 5.42× | 5.39× | 5.11× | 4.40× | 46% | |
| Equity share of assets | -52.6% | -3.1% | -36.6% | -65.9% | 7.0% | 64.1% | 11% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-163 M | $-97 M | $-77 M | $-88 M | $-86 M | $-40 M | 15% | |
| Free cash flow margin | -148.2% | -107.4% | -92.6% | -136.4% | -178.3% | -61.6% | 35% | |
| Capital spending share of revenue | 0.3% | 0.3% | 0.2% | 0.4% | 1.6% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.45× | 0.39× | 0.53× | 0.50× | 0.40× | 0.26× | 67% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Asset turnover
- Revenue divided by total assets (average of the year).